These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3726800)

  • 1. PROPLEX vs. PROPLEX SX: a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII.
    Gomperts ED; Fannon RB; Lee ML; Kingdon HS; Kantrowitz JL; Addiego JE; Carney J; Corrigan JJ; Hathaway W; Hilgartner MW
    Thromb Res; 1986 Jun; 42(6):789-96. PubMed ID: 3726800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.
    Lusher JM; Blatt PM; Penner JA; Aledort LM; Levine PH; White GC; Warrier AI; Whitehurst DA
    Blood; 1983 Nov; 62(5):1135-8. PubMed ID: 6414555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.
    Lusher JM; Shapiro SS; Palascak JE; Rao AV; Levine PH; Blatt PM
    N Engl J Med; 1980 Aug; 303(8):421-5. PubMed ID: 6771653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
    Kelly P; Penner JA
    JAMA; 1976 Nov; 236(18):2061-4. PubMed ID: 989788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors.
    Lusher JM
    Scand J Haematol Suppl; 1984; 40():195-202. PubMed ID: 6433452
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of hemophilia.
    Rodeghiero F
    Ric Clin Lab; 1985; 15(4):289-303. PubMed ID: 3914697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Substitution therapy of hemorrhagic diseases].
    Haupt H
    Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
    [No Abstract]   [Full Text] [Related]  

  • 8. A survey of the effectiveness of prothrombin complex concentrates in controlling hemorrhage in patients with hemophilia and anti-Factor VIII antibodies.
    Blatt PM; Ménaché D; Roberts HR
    Thromb Haemost; 1980 Aug; 44(1):39-42. PubMed ID: 6775386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
    Abildgaard CF; Britton M; Harrison J
    J Pediatr; 1976 Feb; 88(2):200-5. PubMed ID: 1249680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR; Kevy SV
    Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a heated prothrombin complex concentrate in hemophiliacs with inhibitors.
    Mannucci PM; Mari D; Pareti FI
    Thromb Haemost; 1987 Dec; 58(4):1090-1. PubMed ID: 3127920
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of non-activated prothrombin complex concentrate (Proplex ST) on intraperitoneal hematoma in a hemophilia A patient with a factor VIII inhibitor.
    Kagawa H; Yasuzawa M; Ozaki Y; Yamamoto Y; Katsurada T; Nomura S; Okubo S; Fukuhara S
    Intern Med; 1996 Apr; 35(4):319-22. PubMed ID: 8739790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
    Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
    Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated Proplex for the haemophiliac with inhibitors. A case report.
    Hesseling PB
    S Afr Med J; 1979 Jul; 56(3):108-10. PubMed ID: 494025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition considerations for extended half-life factor products.
    Croteau SE; Neufeld EJ
    Haemophilia; 2015 May; 21(3):285-288. PubMed ID: 25855484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.